Horizon Discovery Group plc Director/PDMR Shareholding (8359Q)

TIDMHZD

RNS Number : 8359Q

Horizon Discovery Group plc

02 December 2016

Horizon Discovery Group plc

Director/PDMR Shareholding

Cambridge, UK, 2 December 2016: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or the "Company"), the world leader in the application of gene editing technologies, today announces that on 2 December 2016 Dr Susan Galbraith, a Non-Executive Director of the Company, purchased a total of 40,000 ordinary shares of 1p each in the Company at a price of 119.75 pence per share. Following this purchase of shares Dr Galbraith is interested in a total of 40,000 ordinary shares of 1p each in the Company representing approximately 0.04% of Horizon's issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1     Details of the person discharging managerial 
        responsibilities/person closely associated 
----  ---------------------------------------------------------- 
 a)    Name                       Dr Susan Galbraith 
----  -------------------------  ------------------------------- 
 2     Reason for the notification 
----  ---------------------------------------------------------- 
 a)    Position/status            Non-Executive Director 
----  -------------------------  ------------------------------- 
 b)    Initial                    Initial Notification 
        notification 
        /Amendment 
----  -------------------------  ------------------------------- 
 3     Details of the issuer, emission allowance market 
        participant, auction platform, auctioneer or 
        auction monitor 
----  ---------------------------------------------------------- 
 a)    Name                       Horizon Discovery Group plc 
----  -------------------------  ------------------------------- 
 b)    Legal Entity               N/A 
        Identifier 
----  -------------------------  ------------------------------- 
 4     Details of the transaction(s): section to be 
        repeated for (i) each type of instrument; (ii) 
        each type of transaction; (iii) each date; 
        and (iv) each place where transactions have 
        been conducted 
----  ---------------------------------------------------------- 
 a)    Description                Ordinary shares of 1.0p each 
        of the financial 
        instrument, 
        type of 
        instrument                 GB00BK8FL363 
 
        Identification 
        code 
----  -------------------------  ------------------------------- 
 b)    Nature of                  Purchase of shares 
        the transaction 
----  -------------------------  ------------------------------- 
 c)    Currency                   GBP 
----  -------------------------  ------------------------------- 
 d)    Price(s)                   Price(s)        Volume(s) 
        and volume(s) 
----  -------------------------  --------------  --------------- 
                                  119.75p         40,000 
 ------------------------------  --------------  --------------- 
 
 e)    Aggregated 
        information 
   - Aggregated 
    volume 
   - Price                         40,000 
   - Aggregated                     119.75p 
    total 
                                    GBP47,900 
 ------------------------------  ------------------------------- 
 f)    Date of                    2 December 2016 
        the transaction 
----  -------------------------  ------------------------------- 
 g)    Place of                   London Stock Exchange, AIM 
        the transaction 
----  -------------------------  ------------------------------- 
 

- ENDS -

For further information from Horizon Discovery Group plc, please contact:

Horizon Discovery Group plc

Darrin Disley, Chief Executive Officer

Richard Vellacott, Chief Financial Officer

Chris Claxton, VP Investor Relations

Tel: [phone]

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Susan Stuart / Matthew Neal / Melissa Gardiner

Tel: [phone]

Email: [e-mail]

Numis Securities Limited (Joint Broker and NOMAD)

Michael Meade / Freddie Barnfield

Tel: [phone]

RBC Capital Markets (Joint Broker)

Paul Tomasic / Marcus Jackson

Tel: [phone]

About Horizon Discovery Group plc www.horizondiscovery.com

Horizon Discovery Group plc (LSE: HZD) ("Horizon"), is a world-leading gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health.

Horizon's core capabilities are built around its proprietary translational genomics platform, a highly precise and flexible suite of gene editing tools (rAAV, ZFN and CRISPR) able to alter almost any gene sequence in human or mammalian cell-lines.

Horizon offers over 23,000 catalogue products and related research services, almost all of which are based on the generation and application of cell and in vivo models that accurately recapitulate the disease-causing genetic anomalies found in diseases like cancer. Horizon's commercial offering has been adopted by c. 1,600 unique research organisations in over 50 countries as well as in the Company's own R&D pipeline to support a greater understanding of the genetic drivers of disease and the development of molecular, cell and gene therapies that can be prescribed on a personalised basis.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD".

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHFLLFBQLFLFBD

(END) Dow Jones Newswires

December 02, 2016 06:30 ET (11:30 GMT)